

MATERIAL SAFETY DATA SHEET

Product Name: Atropine Sulfate Injection, USP

1. CHEMICAL PRODUCT AND COMPANY INFORMATION

Manufacturer Name Hospira, Inc.

And Address 275 North Field Drive

Lake Forest, Illinois 60045

USA

Emergency Telephone

CHEMTREC: 800 424-9300

Hospira, Inc.

224 212-2055

Product Name Atropine Sulfate Injection, USP

Synonyms None

2. COMPOSITION/INFORMATION ON INGREDIENTS

Component	Approximate Percent by Weight	CAS Number	RTECS Number
Atropine Sulfate	< 0.01	55-48-1	CK2450000
Water	99	7732-18-5	ZC0110000

3. HAZARD INFORMATION

Emergency Overview In clinical use, this material reverses the effects of acetylcholine in the body

producing changes on many organ systems including the eyes, gastrointestinal tract, heart, lung and central nervous system. The active ingredient is considered

to be toxic by ingestion.

Occupational Exposure

Potential

Information on the absorption of this compound via ingestion,

inhalation or skin contact is not available. Avoid liquid aerosol generation and

skin contact with solution.

Signs and Symptoms No signs or symptoms from occupational exposure are known. In clinical use,

atropine can cause suppressed salivation, dilated pupils, blurred vision, hot/dry sensation, disorientation, increased heart rat, constipation, nausea, urinary retention and hesitancy, palpitation, dizziness, drowsiness, decreased bronchi secretion, photophobia, dry mouth, fever, glaucoma, difficulty breathing,

flushing, rashes and vomiting..

Medical Conditions Aggravated by Exposure

Sensitivity to atropine and belladonna alkaloids. Concurrent glaucoma, tachycardia, gastrointestinal or biliary tract obstruction. Prostate hypertrophy.

Product Name: Atropine Sulfate Injection, USP

5. FIRST AID MEASURES

Eye Contact: Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

Skin Contact: Remove from source of exposure. Flush with copious amounts of water. If

irritation persists or signs of toxicity occur, seek medical attention. Provide

symptomatic/supportive care as necessary.

Inhalation: Remove from source of exposure. If signs of toxicity occur, seek medical

attention. Provide symptomatic / supportive care as necessary.

Ingestion: Remove from source of exposure. If signs of toxicity occur, seek medical

attention. Provide symptomatic / supportive care as necessary.

5. FIRE FIGHTING MEASURES

Flammability: Non-flammable.

Fire & Explosion

Hazard:

None

Extinguishing Media: Use extinguishing media appropriate for the underlying cause of fire.

Special Fire Fighting

Procedures

No special provisions required beyond normal fire fighting equipment such as flame and chemical resistant clothing and self contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Spill Cleanup and Disposal Absorb liquid with suitable material and clean affected area with soap and

water. Dispose of materials according to the applicable federal, state, or local

regulations.

7. HANDLING AND STORAGE

Handling No special handling required.

Storage No special storage required for hazard control. For product protection store at

controlled room temperature of 15-30°C (59-86°F).

Special Precautions Protect from freezing and extreme heat.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Exposure Guidelines

		Exposure limits			
Component	OSHA-PEL	ACGIH-TLV	Hospira EEL		
Atropine Sulfate	8 hr TWA: Not	8 hr TWA: Not	9 hr TWA: 4 mag/m ²		
	Established	Established	8 hr TWA: 4 mcg/m3		

Notes: OSHA PEL: US Occupational Safety and Health Administration – Permissible Exposure Limit

ACGIH TLV: American Conference of Governmental Industrial Hygienists – Threshold Limit Value.

EEL: Employee Exposure Limit.
TWA: 8 hour Time Weighted Average.
STEL: 15-minute Short Term Exposure Limit.

Product Name: Atropine Sulfate Injection, USP

Respiratory Protection Respiratory protection is not needed during normal product use.

Skin Protection If solution contact with unprotected skin is likely, use of impervious gloves is a

prudent practice.

Eye Protection Eye protection is not required during expected product use conditions but may

be warranted should a splash potential exist.

Engineering Controls Engineering controls are not needed during normal product use conditions.

9. PHYSICAL/CHEMICAL PROPERTIES

Appearance/Physical Clear liquid

State

Odor None

Boiling Point Approximately that of water (100 °C, 212 °F). **Freezing Point** Approximately that of water (0°C, 32 °F).

Vapor Pressure Approximately that of water (17.5 mm Hg at 20 °C).

Vapor Density (Air=1)Not ApplicableEvaporation RateNot ApplicableBulk DensityNot Applicable

Specific Gravity Approximately that of water (1.0). **Solubility** Soluble in water, methanol, ethanol

pH 3.5 - 6.5

10. STABILITY AND REACTIVITY

Chemical Stability Stable under standard use and storage conditions.

Incompatibilities None

Hazardous Oxides of nitrogen and sulfur.

Decomposition Products

Hazardous None

Polymerization

11. TOXICOLOGICAL INFORMATION:

Toxicity

Ingredient(s)	Percent	Test Type	Value	Units	Species
Atropine Sulfate	100	LD50	468-765	mg/kg	Rats, Mice

Mutagenicity Not determined.

Target Organ Effects Atropine is a drug that is used to reverse the effects of acetylcholine at post-

ganglionic receptors in the body. It is a potent bronchodilator. When applied

directly to the eyes, it dilates the pupils.

Product Name: Atropine Sulfate Injection, USP

12. ECOLOGICAL INFORMATION:

Aquatic Toxicity Not determined.

13. DISPOSAL CONSIDERATIONS:

Waste Disposal Disposal should be performed in accordance with the federal, state or local

regulatory requirements.

Container Handling Dispose of container and unused contents in accordance with federal, state,

and Disposal and local regulations.

14. TRANSPORTATION INFORMATION

DOT Not Regulated

Notes: DOT - US Department of Transportation Regulations

15. REGULATORY INFORMATION

TSCA Status Atropine Sulfate is listed on the TSCA inventory.

CERCLA Status Not Regulated SARA Status Not Regulated RCRA Status Not Regulated PROP 65 (Calif.) Not Regulated

Notes: TSCA Toxic Substance Control Act

CERCLA, US EPA law, Comprehensive Environmental Response, Compensation, and Liability Act

SARA Superfund Amendments and Reauthorization Act RCRA US EPA, Resource Conservation and Recovery Act

Prop 65, California Proposition 65

16. OTHER INFORMATION:

MSDS Coordinator Global Occupational Toxicology

Date Prepared September 15, 2005 Date Revised October 21, 2008

Disclaimer:

The information and recommendations contained herein are based upon tests believed to be reliable. However, Hospira does not guarantee their accuracy or completeness NOR SHALL ANY OF THIS INFORMATION CONSTITUTE A WARRANTY, WHETHER EXPRESSED OR IMPLIED, AS TO THE SAFETY OF THE GOODS, THE MERCHANTABILITY OF THE GOODS, OR THE FITNESS OF THE GOODS FOR A PARTICULAR PURPOSE. Adjustment to conform to actual conditions of usage may be required. Hospira assumes no responsibility for results obtained or for incidental or consequential damages, including lost profits, arising from the use of these data. No warranty against infringement of any patent, copyright or trademark is made or implied.